ANIP vs. MORF, GYRE, LGND, KURA, ZLAB, RCUS, VRNA, DAWN, DVAX, and PCRX
Should you be buying ANI Pharmaceuticals stock or one of its competitors? The main competitors of ANI Pharmaceuticals include Morphic (MORF), Gyre Therapeutics (GYRE), Ligand Pharmaceuticals (LGND), Kura Oncology (KURA), Zai Lab (ZLAB), Arcus Biosciences (RCUS), Verona Pharma (VRNA), Day One Biopharmaceuticals (DAWN), Dynavax Technologies (DVAX), and Pacira BioSciences (PCRX). These companies are all part of the "pharmaceutical preparations" industry.
ANI Pharmaceuticals (NASDAQ:ANIP) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, community ranking, risk, analyst recommendations, media sentiment, earnings and profitability.
ANI Pharmaceuticals has a net margin of 3.86% compared to Morphic's net margin of 0.00%. ANI Pharmaceuticals' return on equity of 18.06% beat Morphic's return on equity.
76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 94.3% of Morphic shares are held by institutional investors. 12.7% of ANI Pharmaceuticals shares are held by insiders. Comparatively, 28.1% of Morphic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
ANI Pharmaceuticals received 347 more outperform votes than Morphic when rated by MarketBeat users. Likewise, 64.59% of users gave ANI Pharmaceuticals an outperform vote while only 59.54% of users gave Morphic an outperform vote.
ANI Pharmaceuticals has higher revenue and earnings than Morphic. Morphic is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, ANI Pharmaceuticals had 2 more articles in the media than Morphic. MarketBeat recorded 10 mentions for ANI Pharmaceuticals and 8 mentions for Morphic. Morphic's average media sentiment score of 1.15 beat ANI Pharmaceuticals' score of 0.14 indicating that Morphic is being referred to more favorably in the news media.
ANI Pharmaceuticals presently has a consensus price target of $80.00, suggesting a potential upside of 22.40%. Morphic has a consensus price target of $51.50, suggesting a potential upside of 83.47%. Given Morphic's higher probable upside, analysts clearly believe Morphic is more favorable than ANI Pharmaceuticals.
ANI Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Morphic has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.
Summary
ANI Pharmaceuticals beats Morphic on 11 of the 17 factors compared between the two stocks.
Get ANI Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ANI Pharmaceuticals Competitors List
Related Companies and Tools
